Berberine attenuates isoniazid-induced hepatotoxicity by modulating peroxisome proliferator-activated receptory γ, oxidative stress and inflammation

International Journal of Pharmacology

Volumn 10, Issue 8, 2014, Pages 451-460

  Mahmoud, Ayman M ^a   Germoush, Mousa O ^b   Soliman, Ayman S ^a  

^a BENI SUEF UNIVERSITY   (Egypt)

^b JOUF UNIVERSITY   (Saudi Arabia)

Author keywords

Berberine; Hepatotoxicity; Inflammation; Isoniazid; Oxidativestress; PPARs

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BERBERINE; I KAPPA B KINASE BETA; INTERLEUKIN 1BETA; ISONIAZID; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; INFLAMMATION; LIPID PEROXIDATION ASSAY; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; RAT; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

EID: 84914159287     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2014.451.460     Document Type: Article

References (83)

1. Bagi, z., A. Koller and G. Kaley. 2004. PPARy activation. by reducing oxidative stress, mcreases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol., 286: H742-H748.
2. Beltran, B., A. Mathur, M.R. Duchen, J.D. Erusalimsky and S. Moncada, 2000. The effect of nitric oxide on cell respiration: A key to nnderstanding its role in cell survival or death. Proc. Natl. Acad. Sci. USA, 97: 14602-14607.
3. Beutler, E., O. Duron and B.M. Kelly. 1963. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 61: 882-888.
4. Bhutada, P., Y. Mnndhada, K. Bansod, S. Tawari and S. Patil et al., 2011. Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfnnction in rat model of streptozotocin-induced diabetes. Behav. Brain Res. 220:30-41.
5. Boelsterli, U.A., 2002. Mechainsms of NSAID-induced hepatotoxicity. Drug Saf., 25: 633-648.
6. CCAC., 1993. Guide to the Care and Use of Experimental Animals. Vol. 2, Canadian Conncil on Animal Care, Ottawa, Ontario, Canada.
7. Center for Disease Control and Prevention, 2010. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States. 2004-2008. MMWRMorb. Mortal. Wkly. Rep. 59: 224-229.
8. Chen, F.L., Z.H. Yang, Y. Liu, L.X. Li and W.C. Liang et al. 2008. Berberine inhibits the expression of TNFa. MCP-1 and IL-6 in AcLDL­ stimulated macrophages through PPARy pathway. Endocrine. 33: 331-337.
9. Chinetti, G., J.C. Fruchart and B. Staels. 2000. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49: 497-505.
10. Cohen, G., D. Dembiec and J. Marcus, 1970. Measurement of catalase activity in tissue extracts. Ann. Biochem., 34: 30-38.
11. Czaja, M.J., 2007. Cell signaling in oxidative stress­induced liver injury. Semin. Liver Dis., 27: 378-389.
12. De Bosscher, K., W.V. Berghe and G. Haegeman, 2006. Cross-talk between nuclear receptors and nuclear factor eB. Oncogene. 25: 6868-6886.
13. Decker, M., H. Hofflich and A.N. Elias. 2008. Thiazolidinediones and the preservation of -cell fnnction, cellular proliferation and apoptosis. Diabetes Obesity Metab. 10: 617-625.
14. Dinarello, C.A., 2011. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood, 117: 3720-3732.
15. Dobrian, A.D., S.D. Schriver, A.A. Khraibi and R.L. Prewitt, 2004. Pioglitazone prevents hypertension and reduces oxidative stress in diet­ induced obesity. Hypertension, 43: 48-56.
16. Domitrovic, R., H. Jakovac, V.V. Marchesi and B. Blazekovic, 2013. Resolution of liver fibrosis by isoquinoline alkaloid berberine in CC14 -intoxicated mice is mediated by suppression of oxidative stress and upregulation of MMP-2 expression. J. Med. Food. 16: 518-528.
17. Ergul, Y., T. Erkan, H. Uzun, H. Gene, T. Altug and E. Erginoz, 2010. Effect of vitamin Con oxidative liver injury due to isoniazid in rats. Pediatr. Int., 52: 69-74.
18. Forstermann, U. and W.C. Sessa, 2012. Nitric oxide synthases: Regulation and fnnction. Eur. Heart J., 33: 829-837.
19. Franco, R., O.J. Schonveld, A. Pappa and M.I. Panayiotidis. 2007. The central role of glutathione in the pathophysiology of human diseases. Arch. Physiol. Biochem. 113: 234-258.
20. Garg, R., Y. Kumbkarni, A. Aljada, P. Mohanty, Koul, A., E. Amoul, N. Louins, J. Guillemont, H. Ghanirn, W. Hamouda and P. Dandom. 2000. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension, 36: 430-435.
21. Germoush, M.O. and A.M. Mahmoud. 2014. Berberine mitigates cyclophosphamide-induced hepatotoxicity by modulating antioxidant status and inflammatory cytokines. J. Cancer Res. Clin. Oncol., 140: 1103-1109.
22. Girnun, G.D., F.E. Domann, S.A. Moore and M.E. C. Robbins. 2002. Identification of a frmctional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol. Endocrinol., 16: 2793-2801.
23. Gong, P., H. Xu, J. Zhang and Z. Wang. 2012. PPAR expression and its association with SOD and NF-KB in rats with obstructive jmmdice. Biomed. Res.-India, 23: 551-560.
24. Guo, Y., C. Pope, X Cheng, H. Zhou and C.D. Klaassen. 2011. Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice. J. Etlmopharmacol., 138: 111-118.
25. Hara, M.R., N. Agrawal, S.F. Kim, M.B. Cascio and M. Fujirnuro et al., 2005. S-introsylated GAPDH initiates apoptotic cell death by nuclear translocation following Siahl binding. Nat. Cell Biol., 7: 665-674.
26. Houstis, N., E.D. Rosen and E.S. Lander, 2006. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature, 440: 944-948.
27. Huang, Y.S., H.D. Chern, W.J. Su, J.C. Wu and S.L. Lai et al., 2002. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 35: 883-889.
28. Huang, Y.S. 2007. Genetic polymorphisms of chug­ metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injrny. Expert Opin. Drug Metab. Toxicol., 3: 1-8.
29. Huang, Y.S., 2014. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injrny. J. Chin. Med. Assoc. 77: 169-173.
30. Ishida, Y., T. Kondo, T. Ohshima, H. Fujiwara and M.N. Iwakura. 2002. A pivotal involvement of IFN-y in the pathogenesis of acetaminophen-induced acute liver injury. FASEB. J. 16: 1227-1236.
31. Kaplan, L.A. and A.J. Pesce. 1984. Cliincal Chemistry: Theory, Analysis and Correlation. Mosby Inc., St. Louis. MO. USA., pp: 1032-1036.
32. Kar, M. and D. Mishra, 1976. Catalase, peroxidase and polyphenoloxidase activities during nee leaf senescence. Plant Physiol., 57: 315-319.
33. K. Andries. 2011. The challenge of new diug discovery for tuberculosis. Nature, 469: 483-490.
34. Kulkarin, S.K. and A. Dhir. 2010. Berberine: A plant alkaloid with therapeutic potential for central nervous system disorders. Phytother. Res. 24: 317-324.
35. Kumar, G., G.S. Banu, V. Kanmn and M.R. Pandian, 2005. Antihepatotoxic effect of -carotene on paracetamol induced hepatic damage in rats. Ind. J. Exp. Biol., 43: 351-355.
36. Kuo, C.L., C.W. Chi and T.Y. Liu. 2004. The anti­ inflammatory potential of berberine in vitro and in viva. Cancer Lett., 203: 127-137.
37. Lawrence, T., D.W. Gilroy, P.R. Colville-Nash and D.A. Willoughby. 2001. Possible new role for NF-KB in the resolution of inflammation. Nat. Med., 7: 1291-1297.
38. Livak, K.J. and T.D. Schmittgen, 2001. Amlysis of relative gene expression data using real-time quantitative PCR and the 2 AAcT method. Methods. 25: 402-408.
39. Mahmoud, A.M., 2014. Hesperidin protects against cyclophosphamide-induced hepatotoxicity by upregulation of PPARy and abrogation of oxidative stress and inflammation. Can. J. Physiol. Phannacol., 92: 71 7-724.
40. Marfella, R., M. D'Amico, K. Esposito, A. Baldi and C. DiFilippo et al., 2006. The Ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques effects of rosiglitazone treatment. Diabetes. 55: 622-632.
41. Marklund, S. and G. Marklund. 1974. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem. 47: 469-474.
42. Marra, F., E. Efsen, R.G. Romanelli, A. Caligiuri and S. Pastacaldi et al., 2000. Ligands of peroxisome proliferator-activated receptor y modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology. 119: 466-478.
43. Martindale, J.L. and N.J. Holbrook. 2002. Cellular response to oxidative stress: Signaling for suicide and survival. J. Cell. Physiol., 192: 1-15.
44. Matata, B.M. and M. Galinanes, 2002. Peroxynitrite is an essential component of cytokines production mechanism in hwnan monocytes through modulation of nuclear factor-KB DNA binding activity. J. Biol. Chern. 277: 2330-2335.
45. McKim, S.E., E. Gabele, F. Isayama, J.C. Lambert and L.M. Tucker et al., 2003. Inducible nitric oxide synthase is required in alcohol-induced liver injrny: Studies with knockout m1ce. Gastroenterology, 125: 1834-1844.
46. Metushi, I.G., P. Cai, X. Zhu, T. Nakagawa and J.P. Uetrech. 2011. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin. Pharmacal. Ther., 89: 911-914.
47. Mohammed, N.A., S.A. El-Aleem, H.A. El-Hafiz and R.F. McMahon, 2004. Distribution of constitutive (COX-I) and inducible (COX-2) cyclooxygenase in postviral hlllllan liver cirrhosis: A possible role for COX-2 in the pathogenesis of liver cirrhosis. J. Clin. Pathol., 57: 350-354.
48. Montgomery, H. and F.J. Dymock. 1961. Determimtion of nitrite in water. Amlyst. 86: 414-416.
49. Muriel, P., 2007. Cytokines in Liver Diseases. In: Hepatotoxicity: From Genomics to In Vitro and In Viva Models. Sahu, S. (Ed.). John Wiley and Sons. New York. pp: 371-389.
50. Nencini, C., G. Giorgi and L. Micheli, 2007. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine. 14: 129-135.
51. Ogawa, S., J. Lozach, C. Benner, G. Pascual and R.K. Tangirala et al., 2005. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell. 122: 707-721.
52. Okuno, Y., M. Matsuda, H. Kobayashi, K. Morita and E. Suzuki et al., 2008. Adipose expression of catalase is regulated via a novel remote PPARy­ responsive region. Biochem. Biophys. Res. Commnn., 366: 698-704.
53. Palanisamy, N. and S. Manian, 2012. Protective effects of Asparagus racemosus on oxidative damage in isoniazid-induced hepatotoxic rats: An in vivo study. Toxicol. Ind. Health, 28: 238-244.
54. Pascual, G., A.L. Fong, S. Ogawa, A. Gamliel and A.C. Li et al. 2005. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-y. Nature. 437: 759-763.
55. Perry, G., A.K. Raina, A. Nnnomura, T. Wataya, L.M. Sayre and M.A. Smith, 2000. How important is oxidative damage? Lessons from Alzheimer's disease. Free Radic. Biol. Med., 28: 831-834.
56. Peyrou, M., P. Ramadori, L. Bourgoin and M. Foti. 2012. PPARs in liver diseases and cancer: Epigenetic regulation by MicroRNAs. PPAR Res., 101155/20121757803
57. Preuss, H.G., S. T. Jarrell, R. Scheckenbach, S. Lieberman and R.A. Anderson, 1998. Comparative effects of chromilllll, vanadilllll and Gymnema sylvestre on sugar-induced blood pressure elevations in SHR. J. Am. Coll. Nutr. 17: 116-123.
58. Rodriguez-Calvo, R., L. Serrano, T. Coll, N. Moullan and R.M. Sanchez et al., 2008. Activation of peroxisome proliferator-activated receptor /0 inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-KB activity via extracellular signal-related kinase 1/2. Diabetes, 57: 2149-2157.
59. Sapakal, V.D., R.V. Ghadge, R.S. Adnaik, N.S. Naikwade and C.S. Magdum. 2008. Comparative hepatoprotective activity of Liv-52 and livomyn against carbon tetrachloride-induced hepatic injury in rats. Int. J. Green Pharm. 2: 79-82.
60. Schumann, G. and R. Klairke. 2003. New IFCC reference procedures for the determination of catalytic activity concentrations of five enzymes in serum: Preliminary upper reference limits obtained in hospitalized subjects. Clin. Chim. Acta. 327: 69-79.
61. Sherlock, S. and J. Dooley. 2002. Drugs and Liver. In: Diseases of the Liver and Biliary System, Sherlock, S. and J. Dooley (Eds.). II th Edri. Blackwell Science Publication, Oxford. UK. ISBN: 9780632055821. pp: 335-363.
62. Shoba, S., P.A. Patil and V. Vivek. 2008. Hepatoprotective activity of Daucus carota L. aqueous extract against paracetamol, isoniazid and alcohol induced hepatotoxicity m male wistar rats. Pharmacologyonline. 3: 776-787.
63. Sodhi, C.P., S.V. Rana, S.K. Mehta, K. Vaiphei, S. Attari and S. Mehta. 1997. Study of oxidative-stress in isoniazid-rifampicin induced hepatic injury in yonng rats. Drug Chern. Toxicol., 20: 255-269.
64. Soldo-Juresa, D. and Z. Metelko. 2009. PPARy-a new concept of treatment? Diabetol. Croat., 38: 23-29.
65. Swamy, A.H.M.V., R.V. Kulkarni, A.H.M. Thippeswamy, B.C. Koti and A. Gore. 2010. Evaluation of hepatoprotective activity of Cissus quadrangularis stem extract against isoniazid-induced liver damage in rats. Indian J. Pharmacal., 42: 397-400.
66. Tacke, F., T. Luedde and C. Trautwein, 2009. Inflammatory pathways in liver homeostasis and liver injury. Clin. Rev. Allergy Immunol., 36: 4-12.
67. Tafazoli, S., D.D. Spehar and P.J. O'Brien, 2005. Oxidative stress mediated idiosyncratic drug toxicity. Drug Metab. Rev. 37: 311-325.
68. Tang, J., Y. Feng, S. Tsao, N. Wang, R. Curtain and Y. Wang, 2009. Berberine and coptidis rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations. J. Ethnophannacol., l26: 5-17.
69. Tarantino, G., S. Savastano and A. Colao, 2010. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor!adipokine imbalance. World J. Gastroenterol., 16: 4773-4783.
70. Timbrell, J.A., J.R. Mitchell, W.R. Snodgrass and S.D. Nelson, 1980. Isoniazid hepatoxicity: The relationship between covalent binding and metabolism in vivo. J. Pharmacal. Exp. Ther., 213: 364-369.
71. Valko, M. D., Leibfritz, J. Moncol, M.T.D. Cronin, M. Maztrr and J. Telser, 2007. Free radicals and antioxidants in normal physiological frmctions and human disease. Int. J. Biochem. Cell Biol., 39: 44-84.
72. Vieira, H.L., A.S. Belzacq, D. Haouzi, F. Bemassola and I. Cohen et al., 2001. The adenine nucleotide translocator: A target of nitric oxide, peroxynitrite and 4-hydroxynonenal. Oncogene. 20: 4305-4316.
73. Vuddanda, P.R., S. Chakraborty and S. Singh, 2010. Berberine: A potential phytochemical with multispectrum therapeutic activities. Exp. Opin. Invest. Drugs. 19: 1297-1307.
74. Vuillelllllier, N., M.F. Rossier, A. Chiappe, F. Degownois and P. Dayer et al., 2006. CYP2El genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur. J. Clin. Phannacol., 62: 423-429.
75. Wang, Y., T. Campbell, B. Perry, C. Beaurepaire and L. Qin, 2011. Hypoglycemic and insulin-sensitizing effects of berberine m high-fat diet-and streptozotocin-induced diabetic rats. Metabolism, 60: 298-305.
76. Webster, D. 1974. A study of the interaction of bromocresol green with isolated sennn globulin fractions. Clin. Chirn. Acta. 53: 109-115.
77. Wenger, C., A. Kaplan, F.F. Rubaltelli and C. Hammerman, 1984. Alkaline Phosphatase. In: Clinical Chemistry: Theory. Analysis and Correlation. Kaplan. L.A. and A.J. Pesce. (Eds.). The C.V. Mosby Co. St. Louis. Toronto. Princeton. pp: 1094-1098.
78. Yin, J., H. Xing and J. Ye. 2008. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism, 57:712-717.
79. Yokozawa, T., A. Ishida, E.J. Cho, H.Y. Kim, Y. Kashiwada and Y. Ikeshiro, 2004. Coptidis Rhizoma: Protective effects against peroxynitrite-induced oxidative damage and elucidation of its active components. J. Phann. Phannacol., 56: 547-556.
80. Zhang, Y., X. Li, D. Zou, W. Liu and J. Yang et al. 2008. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J. Clin. Endocrinol. Metab. 93: 2559-2565.
81. Zhang, Q., X. Xiao, K. Feng, T. Wang and W. Li et al. 2011. Berberine moderates glucose and lipid metabolism through multi pathway mechanism. Evid. Based Complement. Altemat. Med., 10.1155/2011/924851
82. Zhang, F., Y. Lu and S. Zheng. 2012. Peroxisome proliferator-activated receptor-y cross-regulation of signaling events implicated in liver fibrogenesis. Cell. Signalling. 24: 596-605.
83. Zhou, J.Y. and S.W. Zhou. 2007. Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae. Yao Xue Xue Bao, 42: 1243-1249.